C 82

Drug Profile

C 82

Alternative Names: C-82; PRI-724 prodrug

Latest Information Update: 13 Oct 2016

Price : $50

At a glance

  • Originator PRISM BioLab; University of Southern California
  • Developer PRISM Pharma Co
  • Class Small molecules
  • Mechanism of Action Beta catenin inhibitors; CREB-binding protein inhibitors; Wnt signalling pathway inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Plaque psoriasis; Scleroderma

Most Recent Events

  • 01 Jun 2015 Phase-I/II clinical trials in Plaque psoriasis in Germany (Topical) (NCT02432027)
  • 01 Jun 2015 Phase-I/II clinical trials in Scleroderma in USA (Topical)
  • 28 Apr 2015 Prism Pharma plans a phase I/II trial for Plaque psoriasis in Germany (NCT02432027)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top